A company rich in history, yet poised for the future.
One day, addiction will no longer be viewed through the social lens of scorn and shame. One day, addiction will no longer be a global human crisis. Our Vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction.
Until that day comes, we will continue to pioneer life-transforming treatments. And together with healthcare professionals, the public health community, policy makers, payers, and people like you, we will shift public perceptions of these often underserved patient populations, humanize their suffering and medicalize addiction as a chronic, relapsing condition that should be treated similarly to other chronic diseases. Together, we will break down barriers to treatment for millions of people across the globe who need it most.
Indivior discovered buprenorphine and helped develop it as a leading evidence-based treatment for opioid dependence.
In 1994, Reckitt Benckiser Group plc (RB) established the Buprenorphine Business Group, to which Indivior can trace its history of over 20 years. Following the September 2014 demerger from RB, Indivior PLC was listed as an independent company on the London Stock Exchange.
From our early days as part of RB, to the 2014 demerger, to today, we have always remained focused on patient needs.
Over twenty years ago, the treatment environment for people struggling with addiction was very different. There were limited available treatment options and few medical professionals who could treat those suffering from this disease in an office-based setting. Indivior drove the movement to have opioid use disorder recognized as a chronic medical condition rather than a criminal activity, expanding the availability of treatment options beyond the clinical setting in the US so that patients could have the flexibility to receive treatment in the privacy of a physician’s office, as they do today. We recognized that a shift in mindset was crucial in order for people to access treatment and for addiction to be normalized as chronical medical condition that should be treated like other chronic conditions. We did this because we believed then, as we do now, that we could make a measurable difference in the lives of patients all over the world.
In 2019, Indivior expanded its treatment portfolio to offer a long-acting injectable medication for the treatment of schizophrenia for adults in the U.S. and announced a licensing agreement with a well-established and experienced partner to bring this treatment to patients in Canada. This marks an important milestone in the diversification of Indivior’s business and commitment to patients and an expansion that is well-aligned with our Vision.
Indivior History Highlights
Buprenorphine Business Group established by Reckitt Benckiser to develop buprenorphine for the treatment of opioid dependence
SUBUTEX® (buprenorphine) approved for treatment of opioid dependence in general medical practice by ANSM (France)
In US, Drug Abuse Treatment Act of 2000 legislation permitted qualified physicians to prescribe and dispense specifically approved Schedule III, IV and V narcotic medications for the treatment of opioid dependence in settings other than an opioid treatment program
FDA approves SUBUTEX® (buprenorphine) Sublingual Tablet (CIII) and SUBOXONE® (buprenorphine and naloxone) Sublingual Tablet (CIII) for treatment of opioid dependence in USA
Reckitt Benckiser Pharmaceuticals launches SUBOXONE® (buprenorphine and naloxone) Sublingual Tablet (CIII) and SUBUTEX® (buprenorphine) Sublingual Tablet (CIII) in USA
SUBOXONE sublingual tablet granted marketing authorization by European Commission
DATA 2000 (US) cap was extended from 30 to 100 patients for physicians with at least one year's clinical experience with buprenorphine
Acquired SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) rights from Monosol RX under licence
Launch of SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) in US
Discontinuation of SUBUTEX® (buprenorphine) Sublingual Tablet (CIII) in US
Launch of SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) in Australia
Discontinuation of SUBUTEX sublingual tablet announced in US
SUBOXONE approved in Malaysia
SUBOXONE film approved for use in both induction and maintenance treatment of opioid dependence in appropriate patients
February 2014, the Indivior entered into an agreement with AntiOp, Inc. to co-develop a naloxone nasal spray to aid in the reversal of opioid overdose with the option to acquire all rights to the product upon receipt of regulatory and marketing approval
May 2014, Indivior entered into a global licensing agreement with XenoPort, Inc. for the development and commercialization of a clinical-stage oral product candidate called arbaclofen placarbil for the treatment of alcohol use disorder
September - Indivior PLC incorporated
December 23rd - Demerger of Reckitt Benckiser Pharmaceuticals Inc. from RB Group; listing as Indivior PLC on London Stock Exchange
EU approved SUBOXONE tablet 16mg/4mg strengths
NALSCUE® naloxone nasal spray received marketing authorization from ANSM (France)
FDA Approves SUBLOCADE™ (Buprenorphine Extended-Release), the First and Only Once-Monthly Injectable Buprenorphine Formulation to Treat Moderate to Severe Opioid Use Disorder
Indivior Announces NDA Acceptance of RBP-7000 Risperidone Monthly Depot
Indivior and Addex Enter Strategic Collaboration to Accelerate Development of GABAB PAMs for Addiction Disorder Treatments
SUBLOCADE™ becomes available in the US
FDA Approves PERSERIS™ the First Once-Monthly Subcutaneous Risperidone-Containing, Long Acting Injectable for the Treatment of Schizophrenia in Adults
PERSERIS™ becomes available in the US